Liaocheng Central Hospital
Welcome,         Profile    Billing    Logout  
 18 Trials 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Xi
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
3
150
RoW
SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
Antengene Corporation
Relapsed or Refractory Multiple Myeloma
12/25
12/25
NCT06439342: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Recruiting
3
20
RoW
Maribavir, TAK-620
Takeda
Cytomegalovirus (CMV)
12/26
12/26
NCT04547049: A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Recruiting
3
176
RoW
Cytarabine, Busulfan, Cyclophosphamide, Me-CCNU, Rabbit antithymocyte globulin, Allogeneic HSCT, Cyclosporin A, Mycophenolate Mofetil, MTX
First Affiliated Hospital of Zhejiang University
Leukemia
09/25
12/25
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Terminated
3
10
RoW
Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA)
TJ Biopharma Co., Ltd.
Myelodysplastic Syndromes(MDS)
04/24
04/24
Haplo-HSCT, NCT06202625: Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After

Recruiting
2/3
142
RoW
avatrombopag, Doptelet, Placebo
Peking University People's Hospital, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University
Thrombocytopenia, Stem Cell Transplant Complications
10/24
10/25
NCT04684147: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
2
100
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Relapsed or Refractory Acute Lymphoblastic Leukemia
09/22
12/26
NCT04716686: Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Recruiting
2
83
RoW
Niraparib
Shandong University, Sun Yat-sen University, Tongji Hospital, Women's Hospital School Of Medicine Zhejiang University, Zai Lab (Shanghai) Co., Ltd.
Endometrial Carcinoma, Serous Carcinoma
12/25
12/26
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting
2
60
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Non-Hodgkin's Lymphoma
03/24
09/25
FUMANBA-1, NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
1/2
132
RoW
CT103A
Nanjing IASO Biotherapeutics Co.,Ltd
Multiple Myeloma
10/22
06/24
SWATCH, NCT05265975: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

Terminated
1/2
54
RoW
ATG-010, Selinexor, Lenalidomide, Rituximab
Antengene Corporation
Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
12/24
12/24
NCT04303247: CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Not yet recruiting
1
30
RoW
CD19 and CD22 targeted CAR-T cells
Xinqiao Hospital of Chongqing, Gracell Biotechnologies (Shanghai) Co., Ltd, 920th Hospital of Joint Logistics Support Force, The Affiliated Hospital Of Guizhou Medical University, Tang-Du Hospital, The General Hospital of Western Theater Command, Chongqing University Cancer Hospital
B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
05/21
05/23
NCT04637269: Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

Recruiting
1
16
RoW
anti-BCMA CAR-T
Xinqiao Hospital of Chongqing, Carbiogene Therapeutics Co. Ltd.
Multiple Myeloma
11/21
11/23
NCT04638270: Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

Not yet recruiting
1
16
RoW
anti-CD19 FasT CAR-T cells
Xinqiao Hospital of Chongqing, Gracell Biotechnologies (Shanghai) Co., Ltd, 920th Hospital of Joint Logistics Support Force, The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Guizhou Medical University, The Second Affiliated Hospital of Kunming Medical University, Chongqing University Cancer Hospital
Lymphoma, Non-Hodgkin
11/21
11/23
NCT04516551: Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

Recruiting
1
18
RoW
anti-CD19 allo-CAR-T cells
Xinqiao Hospital of Chongqing, Gracell Biotechnologies (Shanghai) Co., Ltd, First Affiliated Hospital of Zhejiang University, The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Guizhou Medical University, The General Hospital of Western Theater Command, Chongqing University Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Tang-Du Hospital, 920th Hospital of Joint Logistics Support ForceFirst
Relapsed Adult ALL, B Cell Leukemia
12/21
12/22
NCT04639739: Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.

Not yet recruiting
1
9
RoW
anti-CD19 CAR NK
Xinqiao Hospital of Chongqing, Chongqing Precision Biotech Co., Ltd
NHL
12/21
12/23
NCT04264078: Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Recruiting
1
30
RoW
CD7 UCAR-T cells, Fludarabine, Cytoxan, Melphalan
Xinqiao Hospital of Chongqing, Gracell Biotechnology Shanghai Co., Ltd., 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Guizhou Medical University, Central South University, The First Affiliated Hospital of Kunming Medical College, The General Hospital of Western Theater Command, Second Affiliated Hospital of Xi'an Jiaotong University, Nanfang Hospital of Southern Medical University, Fujian Medical University Union Hospital, The First Affiliated Hospital of Anhui Medical University, Tang-Du Hospital
T-cell Leukemia, T-cell Lymphoma
06/22
06/23
NCT05016063: Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Not yet recruiting
1
32
RoW
Fludarabine, Cytoxan, Dual CD33-CLL1 CAR-T cells
Xinqiao Hospital of Chongqing, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leukemia, Myeloid, Acute
09/22
09/23
NCT05008536: Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Recruiting
1
27
RoW
Anti-BCMA CAR-NK Cells, Fludarabine, Cytoxan
Xinqiao Hospital of Chongqing, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Multiple Myeloma, Refractory
09/22
09/23
NCT05008575: Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
27
RoW
anti-CD33 CAR NK cells, Fludarabine, Cytoxan
Xinqiao Hospital of Chongqing, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leukemia, Myeloid, Acute
12/22
12/23
NCT05443841: Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)

Recruiting
N/A
385
RoW
pleural lavage
Fudan University
Esophageal Cancer
07/24
07/27
NCT06727669: Longitudinal Cohort of Thrombosis and Hemostasis Diseases

Recruiting
N/A
3000
RoW
Peking University People's Hospital
Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation, Thrombophilia, Deep Vein Thrombosis, Pulmonary Embolism, Thrombotic Microangiopathies, Coagulation Factor Deficiency, Hemophilia A, Hemophilia B, Hemophilia B, Acquired, Platelet Dysfunction, Arterial Thromboembolism, Bleeding Disorder, Thrombosis
12/29
12/30
Zhao, Hongyang
STRATEGY, NCT05310968: Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction

Recruiting
4
970
RoW
Tirofiban hydrochloride sodium chloride injection, Tirofiban hydrochloride sodium chloride injection placebo, Aspirin
Beijing Tiantan Hospital, GrandPharma (China) Co., Ltd.
Branch Atheromatous Disease
06/24
09/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Xi
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
3
150
RoW
SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
Antengene Corporation
Relapsed or Refractory Multiple Myeloma
12/25
12/25
NCT06439342: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Recruiting
3
20
RoW
Maribavir, TAK-620
Takeda
Cytomegalovirus (CMV)
12/26
12/26
NCT04547049: A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Recruiting
3
176
RoW
Cytarabine, Busulfan, Cyclophosphamide, Me-CCNU, Rabbit antithymocyte globulin, Allogeneic HSCT, Cyclosporin A, Mycophenolate Mofetil, MTX
First Affiliated Hospital of Zhejiang University
Leukemia
09/25
12/25
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Terminated
3
10
RoW
Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA)
TJ Biopharma Co., Ltd.
Myelodysplastic Syndromes(MDS)
04/24
04/24
Haplo-HSCT, NCT06202625: Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After

Recruiting
2/3
142
RoW
avatrombopag, Doptelet, Placebo
Peking University People's Hospital, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University
Thrombocytopenia, Stem Cell Transplant Complications
10/24
10/25
NCT04684147: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
2
100
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Relapsed or Refractory Acute Lymphoblastic Leukemia
09/22
12/26
NCT04716686: Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Recruiting
2
83
RoW
Niraparib
Shandong University, Sun Yat-sen University, Tongji Hospital, Women's Hospital School Of Medicine Zhejiang University, Zai Lab (Shanghai) Co., Ltd.
Endometrial Carcinoma, Serous Carcinoma
12/25
12/26
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting
2
60
RoW
single dose of CNCT19
Juventas Cell Therapy Ltd.
Non-Hodgkin's Lymphoma
03/24
09/25
FUMANBA-1, NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
1/2
132
RoW
CT103A
Nanjing IASO Biotherapeutics Co.,Ltd
Multiple Myeloma
10/22
06/24
SWATCH, NCT05265975: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

Terminated
1/2
54
RoW
ATG-010, Selinexor, Lenalidomide, Rituximab
Antengene Corporation
Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
12/24
12/24
NCT04303247: CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Not yet recruiting
1
30
RoW
CD19 and CD22 targeted CAR-T cells
Xinqiao Hospital of Chongqing, Gracell Biotechnologies (Shanghai) Co., Ltd, 920th Hospital of Joint Logistics Support Force, The Affiliated Hospital Of Guizhou Medical University, Tang-Du Hospital, The General Hospital of Western Theater Command, Chongqing University Cancer Hospital
B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
05/21
05/23
NCT04637269: Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

Recruiting
1
16
RoW
anti-BCMA CAR-T
Xinqiao Hospital of Chongqing, Carbiogene Therapeutics Co. Ltd.
Multiple Myeloma
11/21
11/23
NCT04638270: Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

Not yet recruiting
1
16
RoW
anti-CD19 FasT CAR-T cells
Xinqiao Hospital of Chongqing, Gracell Biotechnologies (Shanghai) Co., Ltd, 920th Hospital of Joint Logistics Support Force, The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Guizhou Medical University, The Second Affiliated Hospital of Kunming Medical University, Chongqing University Cancer Hospital
Lymphoma, Non-Hodgkin
11/21
11/23
NCT04516551: Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

Recruiting
1
18
RoW
anti-CD19 allo-CAR-T cells
Xinqiao Hospital of Chongqing, Gracell Biotechnologies (Shanghai) Co., Ltd, First Affiliated Hospital of Zhejiang University, The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Guizhou Medical University, The General Hospital of Western Theater Command, Chongqing University Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Tang-Du Hospital, 920th Hospital of Joint Logistics Support ForceFirst
Relapsed Adult ALL, B Cell Leukemia
12/21
12/22
NCT04639739: Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.

Not yet recruiting
1
9
RoW
anti-CD19 CAR NK
Xinqiao Hospital of Chongqing, Chongqing Precision Biotech Co., Ltd
NHL
12/21
12/23
NCT04264078: Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Recruiting
1
30
RoW
CD7 UCAR-T cells, Fludarabine, Cytoxan, Melphalan
Xinqiao Hospital of Chongqing, Gracell Biotechnology Shanghai Co., Ltd., 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Guizhou Medical University, Central South University, The First Affiliated Hospital of Kunming Medical College, The General Hospital of Western Theater Command, Second Affiliated Hospital of Xi'an Jiaotong University, Nanfang Hospital of Southern Medical University, Fujian Medical University Union Hospital, The First Affiliated Hospital of Anhui Medical University, Tang-Du Hospital
T-cell Leukemia, T-cell Lymphoma
06/22
06/23
NCT05016063: Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Not yet recruiting
1
32
RoW
Fludarabine, Cytoxan, Dual CD33-CLL1 CAR-T cells
Xinqiao Hospital of Chongqing, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leukemia, Myeloid, Acute
09/22
09/23
NCT05008536: Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Recruiting
1
27
RoW
Anti-BCMA CAR-NK Cells, Fludarabine, Cytoxan
Xinqiao Hospital of Chongqing, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Multiple Myeloma, Refractory
09/22
09/23
NCT05008575: Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
27
RoW
anti-CD33 CAR NK cells, Fludarabine, Cytoxan
Xinqiao Hospital of Chongqing, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leukemia, Myeloid, Acute
12/22
12/23
NCT05443841: Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)

Recruiting
N/A
385
RoW
pleural lavage
Fudan University
Esophageal Cancer
07/24
07/27
NCT06727669: Longitudinal Cohort of Thrombosis and Hemostasis Diseases

Recruiting
N/A
3000
RoW
Peking University People's Hospital
Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation, Thrombophilia, Deep Vein Thrombosis, Pulmonary Embolism, Thrombotic Microangiopathies, Coagulation Factor Deficiency, Hemophilia A, Hemophilia B, Hemophilia B, Acquired, Platelet Dysfunction, Arterial Thromboembolism, Bleeding Disorder, Thrombosis
12/29
12/30
Zhao, Hongyang
STRATEGY, NCT05310968: Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction

Recruiting
4
970
RoW
Tirofiban hydrochloride sodium chloride injection, Tirofiban hydrochloride sodium chloride injection placebo, Aspirin
Beijing Tiantan Hospital, GrandPharma (China) Co., Ltd.
Branch Atheromatous Disease
06/24
09/24

Download Options